Cargando…
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
BACKGROUND: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechan...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082841/ https://www.ncbi.nlm.nih.gov/pubmed/35527277 http://dx.doi.org/10.1186/s40035-022-00302-4 |
_version_ | 1784703291077165056 |
---|---|
author | Chen, Dongmei Lan, Guihua Li, Ruomeng Mei, Yingxue Shui, Xindong Gu, Xi Wang, Long Zhang, Tao Gan, Chen-Ling Xia, Yongfang Hu, Li Tian, Yuan Zhang, Mi Lee, Tae Ho |
author_facet | Chen, Dongmei Lan, Guihua Li, Ruomeng Mei, Yingxue Shui, Xindong Gu, Xi Wang, Long Zhang, Tao Gan, Chen-Ling Xia, Yongfang Hu, Li Tian, Yuan Zhang, Mi Lee, Tae Ho |
author_sort | Chen, Dongmei |
collection | PubMed |
description | BACKGROUND: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechanisms by which melatonin attenuates tau hyperphosphorylation and tau-related pathologies are not fully understood. METHODS: Immunofluorescence, immunoblotting analysis and thioflavin-S staining were employed to examine the effects of early and late treatment of melatonin on tau-related pathology in hTau mice, in which nonmutated human tau is overexpressed on a mouse tau knockout background. High-throughput microRNA (miRNA) sequencing, quantitative RT-PCR, luciferase reporter assay and immunoblotting analysis were performed to determine the molecular mechanism. RESULTS: We found that both early and late treatment of melatonin efficiently decreased the phosphorylation of soluble and insoluble tau at sites related to AD. Moreover, melatonin significantly reduced the number of neurofibrillary tangles (NFTs) and attenuated neuronal loss in the cortex and hippocampus. Furthermore, using miRNA microarray analysis, we found that miR-504-3p expression was upregulated by melatonin in the hTau mice. The administration of miR-504-3p mimics dramatically decreased tau phosphorylation by targeting p39, an activator of the well-known tau kinase cyclin-dependent kinase 5 (CDK5). Compared with miR-504-3p mimics alone, co-treatment with miR-504-3p mimics and p39 failed to reduce tau hyperphosphorylation. CONCLUSIONS: Our results suggest for the first time that melatonin alleviates tau-related pathologies through upregulation of miR-504-3p expression by targeting the p39/CDK5 axis and provide novel insights into AD treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00302-4. |
format | Online Article Text |
id | pubmed-9082841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90828412022-05-10 Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease Chen, Dongmei Lan, Guihua Li, Ruomeng Mei, Yingxue Shui, Xindong Gu, Xi Wang, Long Zhang, Tao Gan, Chen-Ling Xia, Yongfang Hu, Li Tian, Yuan Zhang, Mi Lee, Tae Ho Transl Neurodegener Research BACKGROUND: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechanisms by which melatonin attenuates tau hyperphosphorylation and tau-related pathologies are not fully understood. METHODS: Immunofluorescence, immunoblotting analysis and thioflavin-S staining were employed to examine the effects of early and late treatment of melatonin on tau-related pathology in hTau mice, in which nonmutated human tau is overexpressed on a mouse tau knockout background. High-throughput microRNA (miRNA) sequencing, quantitative RT-PCR, luciferase reporter assay and immunoblotting analysis were performed to determine the molecular mechanism. RESULTS: We found that both early and late treatment of melatonin efficiently decreased the phosphorylation of soluble and insoluble tau at sites related to AD. Moreover, melatonin significantly reduced the number of neurofibrillary tangles (NFTs) and attenuated neuronal loss in the cortex and hippocampus. Furthermore, using miRNA microarray analysis, we found that miR-504-3p expression was upregulated by melatonin in the hTau mice. The administration of miR-504-3p mimics dramatically decreased tau phosphorylation by targeting p39, an activator of the well-known tau kinase cyclin-dependent kinase 5 (CDK5). Compared with miR-504-3p mimics alone, co-treatment with miR-504-3p mimics and p39 failed to reduce tau hyperphosphorylation. CONCLUSIONS: Our results suggest for the first time that melatonin alleviates tau-related pathologies through upregulation of miR-504-3p expression by targeting the p39/CDK5 axis and provide novel insights into AD treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00302-4. BioMed Central 2022-05-09 /pmc/articles/PMC9082841/ /pubmed/35527277 http://dx.doi.org/10.1186/s40035-022-00302-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chen, Dongmei Lan, Guihua Li, Ruomeng Mei, Yingxue Shui, Xindong Gu, Xi Wang, Long Zhang, Tao Gan, Chen-Ling Xia, Yongfang Hu, Li Tian, Yuan Zhang, Mi Lee, Tae Ho Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease |
title | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease |
title_full | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease |
title_fullStr | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease |
title_full_unstemmed | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease |
title_short | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease |
title_sort | melatonin ameliorates tau-related pathology via the mir-504-3p and cdk5 axis in alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082841/ https://www.ncbi.nlm.nih.gov/pubmed/35527277 http://dx.doi.org/10.1186/s40035-022-00302-4 |
work_keys_str_mv | AT chendongmei melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT languihua melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT liruomeng melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT meiyingxue melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT shuixindong melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT guxi melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT wanglong melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT zhangtao melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT ganchenling melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT xiayongfang melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT huli melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT tianyuan melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT zhangmi melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease AT leetaeho melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease |